Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says

MedPage Today December 4, 2024
Kristen Monaco

— Dual GLP-1/GIP drug yielded an average 47% greater relative weight loss compared to semaglutide

Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on Wednesday.

In topline data from the open-label phase IIIb SURMOUNT-5 trial, people on tirzepatide lost 20.2% of their body weight compared with 13.7% with semaglutide after 72 weeks.

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.

All of the five key secondary endpoints favored tirzepatide,...

Today's Sponsors

Today's Sponsor